Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PVLA Palvella Therapeutics

Closed 12-18 16:00:00 EST

96.24

+4.23

+4.60%

盘后96.24

+0.000.00%

17:40 EST

High96.86	Low92.20	Vol239.29K
Open92.31	D1 Closing92.01	Amplitude5.06%
Mkt Cap1.14B	Tradable Cap688.93M	Total Shares11.84M
T/O22.64M	T/O Rate3.34%	Tradable Shares7.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":96.24,"timestamp":1766091600000,"preClose":92.01,"halted":0,"volume":239286,"hourTrading":{"tag":"盘后","latestPrice":96.24,"preClose":96.24,"latestTime":"17:40 EST","volume":4213,"amount":405466.49,"timestamp":1766097655156},"delay":0,"floatShares":7158500,"shares":11836490,"eps":-3.529122,"marketStatus":"Closed","change":4.23,"latestTime":"12-18 16:00:00 EST","open":92.31,"high":96.86,"low":92.2,"amount":22643026.39356,"amplitude":0.050647,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.529122,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":92.01,"preHourTrading":{"tag":"盘前","latestPrice":92.1,"preClose":92.01,"latestTime":"08:43 EST","volume":932,"amount":86481.8877,"timestamp":1766065390635},"postHourTrading":{"tag":"盘后","latestPrice":96.24,"preClose":96.24,"latestTime":"17:40 EST","volume":4213,"amount":405466.49,"timestamp":1766097655156},"volumeRatio":0.572249,"impliedVol":0.6742,"impliedVolPercentile":0.5556},"requestUrl":"/m/hq/s/PVLA/tweets","defaultTab":"tweets","newsList":[{"id":"2592931271","title":"BUZZ-Palvella Therapeutics climbs after Truist raises PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2592931271","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592931271?lang=en_us&edition=fundamental","pubTime":"2025-12-17 02:38","pubTimestamp":1765910313,"startTime":"0","endTime":"0","summary":"BUZZ-Palvella Therapeutics climbs after Truist raises PT ** Shares of drug developer Palvella Therapeutics PVLA.O rise 6.14% to $94.45** Truist raises price target to $190 from $105, a 113.5% upside to the stock's last close** Truist says a small proof of concept study with co's Qtorin gel delivered sufficient \"de-risking\" of opportunity in patients with cutaneous Venous Malformations, a rare genetic skin condition causing dysfunctional veins** Brokerage says results likely understate peak treatment effect, as improvements were still deepening at 12 weeks** 15 of 15 brokerages rate the stock \"buy\" or \"strong buy\"; median PT is $190 — data compiled by LSEG** As of last close, PVLA up 641.5% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nL4N3XM13Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2591998412","title":"Chardan Boosts Price Target on Palvella Therapeutics to $174 From $110, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591998412","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591998412?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:57","pubTimestamp":1765889870,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $173.47, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2591981213","title":"FDA Grants Fast Track Designation to Palvella Therapeutics’ QTORIN Rapamycin for Angiokeratomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981213","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981213?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888222,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc., a clinical-stage biopharmaceutical company, has received Fast Track Designation from the U.S. Food and Drug Administration  for its investigational drug QTORIN rapamycin for the treatment of angiokeratomas. This designation is intended to facilitate the development and expedite the review of drugs addressing serious conditions with unmet medical needs. Currently, there are no FDA-approved therapies for angiokeratomas, which affect over 50,000 diagnosed patients in the U.S. Palvella plans to initiate a Phase 2 clinical trial for QTORIN rapamycin in the second half of 2026. No other organizations were mentioned as recipients of this regulatory milestone.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL7Y4Fn7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","LU0314104364.USD","IE00B3QW5Z07.USD","PVLA","SG9999014039.USD","LU2210150020.SGD","BK4112","SG9999014021.USD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","LU2210149790.SGD"],"gpt_icon":0},{"id":"2591898141","title":"Palvella Therapeutics Granted FDA Fast Track Designation for Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Angiokeratomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2591898141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591898141?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA4MNKFR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2591398126","title":"Palvella Therapeutics Inc - Plans Phase 2 Trial for Qtorin Rapamycin in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2591398126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591398126?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:30","pubTimestamp":1765888200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA4MNKFR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2591341626","title":"Palvella Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591341626","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591341626?lang=en_us&edition=fundamental","pubTime":"2025-12-16 02:22","pubTimestamp":1765822920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 15, 2025 13:22 ET (18:22 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"gpt_icon":0},{"id":"2591664861","title":"Palvella Therapeutics Reports Positive Phase 2 Results for QTORIN Rapamycin in Cutaneous Venous Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2591664861","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591664861?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796433,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics Inc. announced topline results from its Phase 2 TOIVA study evaluating QTORIN rapamycin for the treatment of cutaneous venous malformations . The data showed that 73% of participants improved on the Overall cVM-IGA at Week 12. QTORIN rapamycin was generally well-tolerated, with no drug-related serious adverse events reported and only mild to moderate treatment-related adverse events, primarily application site reactions. Based on these results, Palvella plans to engage in near-term discussions with the FDA regarding the potential for Breakthrough Therapy Designation and a Phase 3 pivotal study. The results are planned for presentation at future medical meetings. The FDA has previously granted Fast Track Designation to QTORIN rapamycin for the treatment of venous malformations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated cont","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL9Vr03s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","SG9999014013.SGD","BK4139","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","SG9999014005.SGD","SG9999014021.USD","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","BK4588","SG9999014039.USD","PVLA"],"gpt_icon":0},{"id":"2591648659","title":"Palvella Therapeutics Inc - 73% of Participants Improved in Phase 2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591648659?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796413,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL09N:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2591486506","title":"Palvella Therapeutics Inc - Qtorin™ Rapamycin Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2591486506","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591486506?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL09N:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2591164866","title":"Palvella Therapeutics Announces Positive Topline Results From Phase 2 Toiva Clinical Trial of Qtorin™ 3.9% Rapamycin Anhydrous Gel (Qtorin™ Rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease With No FDA-Approved Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591164866?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:00","pubTimestamp":1765796413,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL09N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2589920378","title":"Palvella Therapeutics Inc : Btig Initiates Coverage With Buy Rating; Price Target $167","url":"https://stock-news.laohu8.com/highlight/detail?id=2589920378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589920378?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:56","pubTimestamp":1764939364,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XB0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2589892118","title":"BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892118","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892118?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:46","pubTimestamp":1764938809,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics, Inc. (PVLA) has an average rating of Buy and mean price target of $143.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"gpt_icon":0},{"id":"2589313208","title":"Palvella Therapeutics Initiated at Buy by Craig-Hallum","url":"https://stock-news.laohu8.com/highlight/detail?id=2589313208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589313208?lang=en_us&edition=fundamental","pubTime":"2025-12-05 02:03","pubTimestamp":1764871380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 04, 2025 13:03 ET (18:03 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2585460755","title":"Palvella Therapeutics price target raised to $145 from $87 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585460755?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:15","pubTimestamp":1763993717,"startTime":"0","endTime":"0","summary":"Stifel raised the firm’s price target on Palvella Therapeutics (PVLA) to $145 from $87 and keeps a Buy rating on the shares. Despite the “tremendou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-145-from-87-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-price-target-raised-to-145-from-87-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","SF"],"gpt_icon":0},{"id":"2585614724","title":"Stifel Nicolaus Keeps Their Buy Rating on Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585614724","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585614724?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:17","pubTimestamp":1763986634,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on Palvella Therapeutics today and set a price target of $145.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-keeps-their-buy-rating-on-palvella-therapeutics-pvla-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PVLA","SF"],"gpt_icon":0},{"id":"2584924514","title":"Palvella Therapeutics Shares Gain 11.2% After Raymond James Upgrades to 'Strong Buy' From 'Outperform'","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924514?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:26","pubTimestamp":1763573214,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL4N3WV1KJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2584210269","title":"Palvella Therapeutics Reports Third Quarter 2025 Financial Results And Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2584210269","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584210269?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:20","pubTimestamp":1763572830,"startTime":"0","endTime":"0","summary":"Nov 11 (Reuters) - Palvella Therapeutics Inc ::*PALVELLA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE*PALVELLA THERAPEUTICS INC:  Q3 EPS $-1.03  ((Reuters In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6NCxkK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"gpt_icon":0},{"id":"2584949946","title":"Palvella Therapeutics Raised to Strong Buy From Outperform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949946?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:57","pubTimestamp":1763557020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PVLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:57 ET (12:57 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","RJF"],"gpt_icon":0},{"id":"2584457809","title":"Palvella Therapeutics Inc : Raymond James Raises to Strong Buy From Outperform; Raises Target Price to $143 From $92","url":"https://stock-news.laohu8.com/highlight/detail?id=2584457809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584457809?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:11","pubTimestamp":1763554308,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nFWN3WV0YO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"gpt_icon":0},{"id":"2584945575","title":"Palvella Therapeutics upgraded to Strong Buy from Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2584945575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584945575?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:45","pubTimestamp":1763552709,"startTime":"0","endTime":"0","summary":"Raymond James upgraded Palvella Therapeutics (PVLA) to Strong Buy from Outperform with a price target of $143, up from $92. After further review of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palvella-therapeutics-upgraded-to-strong-buy-from-outperform-at-raymond-james-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RJF","PVLA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pieris.com","stockEarnings":[{"period":"1week","weight":-0.0556},{"period":"1month","weight":0.127},{"period":"3month","weight":0.5584},{"period":"6month","weight":3.1728},{"period":"1year","weight":6.0777},{"period":"ytd","weight":6.6675}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.102904},{"month":2,"riseRate":0.5,"avgChangeRate":0.02179},{"month":3,"riseRate":0.5,"avgChangeRate":0.012293},{"month":4,"riseRate":0.2,"avgChangeRate":-0.082116},{"month":5,"riseRate":0.5,"avgChangeRate":0.168212},{"month":6,"riseRate":0.4,"avgChangeRate":-0.088952},{"month":7,"riseRate":0.727273,"avgChangeRate":0.169693},{"month":8,"riseRate":0.636364,"avgChangeRate":0.117993},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.090465},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.050324},{"month":11,"riseRate":0.545455,"avgChangeRate":0.066832},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.062495}],"exchange":"NASDAQ","name":"Palvella Therapeutics","nameEN":"Palvella Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palvella Therapeutics,PVLA,Palvella Therapeutics股票,Palvella Therapeutics股票老虎,Palvella Therapeutics股票老虎国际,Palvella Therapeutics行情,Palvella Therapeutics股票行情,Palvella Therapeutics股价,Palvella Therapeutics股市,Palvella Therapeutics股票价格,Palvella Therapeutics股票交易,Palvella Therapeutics股票购买,Palvella Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palvella Therapeutics(PVLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palvella Therapeutics(PVLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction